Definite and probable bioresorbable scaffold thrombosis in stable and ACS patients.

[1]  R. Virmani,et al.  Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice. , 2013, JACC. Cardiovascular interventions.

[2]  R. Virmani,et al.  Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application. , 2011, EuroIntervention.

[3]  P. Serruys,et al.  Bioresorbable polymeric vascular scaffolds: a cautionary tale. , 2011, Circulation. Cardiovascular interventions.

[4]  Michail I. Papafaklis,et al.  Fusion of optical coherence tomographic and angiographic data for more accurate evaluation of the endothelial shear stress patterns and neointimal distribution after bioresorbable scaffold implantation: comparison with intravascular ultrasound-derived reconstructions , 2014, The International Journal of Cardiovascular Imaging.

[5]  Giuseppe Biondi-Zoccai,et al.  Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. , 2012, JACC. Cardiovascular interventions.

[6]  P. Serruys,et al.  A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial , 2015, The Lancet.

[7]  E. Edelman,et al.  Stent Thrombogenicity Early in High-Risk Interventional Settings Is Driven by Stent Design and Deployment and Protected by Polymer-Drug Coatings , 2011, Circulation.

[8]  R. Whitbourn,et al.  Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[9]  F. Feres,et al.  Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. , 2007, European heart journal.

[10]  P. Woudstra,et al.  Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent , 2014, American heart journal.